國立虎尾科技大學 |

Current Applications for Overcoming Resistance to Targeted Therapies

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Current Applications for Overcoming Resistance to Targeted Therapies/ edited by Myron R. Szewczuk, Bessi Qorri, Manpreet Sambi.
其他作者:	Szewczuk, Myron R.
面頁冊數:	XVIII, 320 p. 31 illus., 29 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Cancer research. -
電子資源:	https://doi.org/10.1007/978-3-030-21477-7
ISBN:	9783030214777

Current Applications for Overcoming Resistance to Targeted Therapies
Current Applications for Overcoming Resistance to Targeted Therapies[electronic resource] /edited by Myron R. Szewczuk, Bessi Qorri, Manpreet Sambi. - 1st ed. 2019. - XVIII, 320 p. 31 illus., 29 illus. in color.online resource. - Resistance to Targeted Anti-Cancer Therapeutics,202196-5501 ;. - Resistance to Targeted Anti-Cancer Therapeutics,4.

Introduction to the Acquisition of Resistance to Targeted Therapy -- Targeting the Tumor Microenvironment to Overcome Resistance to Targeted Therapy -- Current Challenges and Applications of Oncolytic Viruses in Overcoming Resistance to Therapies in Cancer -- Novel Methods to Overcome Acquired Resistance to Immunotherapy -- Therapies to Overcome Multidrug-Resistant Receptors -- Overcoming Resistance to PARP Inhibition -- Novel Methods of Overcoming HER2 Therapy Resistance in Breast Cancer -- Emerging Novel Therapies for Overcoming Resistance to Targeted Therapies -- Targeting Epigenetic Regulators in Cancer to Overcome Resistance to Targeted Therapy -- Nanomedicine and Drug Delivery Systems in Overcoming Resistance to Targeted Therapy -- Index.

Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.

ISBN: 9783030214777

Standard No.: 10.1007/978-3-030-21477-7doiSubjects--Topical Terms:

1253664
Cancer research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Current Applications for Overcoming Resistance to Targeted Therapies
LDR:03282nam a22004095i 4500 001 1015349
003 DE-He213
005 20200701173145.0
007 cr nn 008mamaa
008 210106s2019 gw | s |||| 0|eng d
020 $a 9783030214777 $9 978-3-030-21477-7
024 7 $a 10.1007/978-3-030-21477-7 $2 doi
035 $a 978-3-030-21477-7
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Current Applications for Overcoming Resistance to Targeted Therapies $h [electronic resource] / $c edited by Myron R. Szewczuk, Bessi Qorri, Manpreet Sambi.
250 $a 1st ed. 2019.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a XVIII, 320 p. 31 illus., 29 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Resistance to Targeted Anti-Cancer Therapeutics, $x 2196-5501 ; $v 20
505 0 $a Introduction to the Acquisition of Resistance to Targeted Therapy -- Targeting the Tumor Microenvironment to Overcome Resistance to Targeted Therapy -- Current Challenges and Applications of Oncolytic Viruses in Overcoming Resistance to Therapies in Cancer -- Novel Methods to Overcome Acquired Resistance to Immunotherapy -- Therapies to Overcome Multidrug-Resistant Receptors -- Overcoming Resistance to PARP Inhibition -- Novel Methods of Overcoming HER2 Therapy Resistance in Breast Cancer -- Emerging Novel Therapies for Overcoming Resistance to Targeted Therapies -- Targeting Epigenetic Regulators in Cancer to Overcome Resistance to Targeted Therapy -- Nanomedicine and Drug Delivery Systems in Overcoming Resistance to Targeted Therapy -- Index.
520 $a Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.
650 0 $a Cancer research. $3 1253664
650 0 $a Molecular biology. $3 583443
650 1 4 $a Cancer Research. $3 668358
650 2 4 $a Molecular Medicine. $3 668353
700 1 $a Szewczuk, Myron R. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1228980
700 1 $a Qorri, Bessi. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1228981
700 1 $a Sambi, Manpreet. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1228982
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030214760
776 0 8 $i Printed edition: $z 9783030214784
776 0 8 $i Printed edition: $z 9783030214791
830 0 $a Resistance to Targeted Anti-Cancer Therapeutics, $x 2196-5501 ; $v 4 $3 1254768
856 4 0 $u https://doi.org/10.1007/978-3-030-21477-7
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)